| Name | Title | Contact Details |
|---|---|---|
Michele Smolin |
General Counsel | Profile |
Biochrom is a Holliston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Excision BioTherapeutics is a private company focused on developing advanced gene editing therapeutics to address the medical need for the treatment of life-threatening disease caused by viral infections. Our mission is to advance gene editing therapeutics for our indications into safe and efficacious medicines that will greatly improve the lives of infected individuals around the world.
BioClin Therapeutics, Inc. is a privately-held biotechnology developing biologics to address medical conditions where there is significant unmet need. Our lead program is a human monoclonal antibody, B-701, that targets and blocks the activity of FGFR3 (fibroblast growth factor receptor 3) and is the most advanced FGFR3-specific antagonist in development. B-701 has been tested in two Phase 1 clinical trials involving 40 patients and demonstrated potential efficacy in patients with metastatic bladder cancer who were receiving it as 2nd line therapy.
Princeton Separations Inc is a Freehold, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
OPK Biotech is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.